Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OTC labeling studies

This article was originally published in The Tan Sheet

Executive Summary

OTC labeling studies: Office of Management & Budget approves FDA label comprehension and preference studies involving 2,100 subjects July 17. The approval allots a timeframe ending Nov. 30 for the research project. However, FDA may have administrative procedures available to obtain additional time. The Nonprescription Drug Manufacturers Association expressed concerns with the studies in a June 13 letter to OMB ("The Tan Sheet" June 23, p. 5). Separately, FDA announced Aug. 1 it is extending the comment period on two additional OTC labeling studies from July 22 to Sept. 30. The studies will assess consumer comprehension of product statements of identity and analgesic alcohol warnings ("The Tan Sheet" June 2, p. 8)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel